ArticleAmerican journal of translational research2026
Predictive value of soluble growth stimulated expression gene 2 (sST2) for recurrence after radiofrequency ablation in patients with atrial fibrillation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the prognostic utility of preoperative soluble growth stimulated expression gene 2 (sST2) for post-ablation Atrial fibrillation (AF) recurrence and develop a multi-marker nomogram to optimize preprocedural risk assessment.
methodsThis monocentric retrospective study enrolled 517 AF patients undergoing radiofrequency ablation (RFA) between January 2020 and December 2024, with a 12-month postprocedural follow-up. We collected baseline clinical characteristics, left atrial diameter (LAD), and serum biomarkers including high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-6 (IL-6), and sST2. Multivariable logistic regression revealed the independent risk factors for recurrence after ablation; we then constructed a nomogram and performed internal validation.
resultsAF recurrence occurred in 172 patients (33.27%). LAD, hs-CRP, NT-proBNP, IL-6, and sST2 were confirmed as independent predictors of recurrence. sST2 demonstrated the strongest individual predictive performance, with an optimal cutoff value of 32.69 ng/mL and an area under the curve (AUC) of 0.825. The combined nomogram achieved AUCs of 0.950 in the training set and 0.935 in the validation set, which was significantly better than the traditional CHA
conclusionsPreoperative sST2 is a robust independent predictor of AF recurrence after RFA. The novel nomogram integrating sST2 with LAD and inflammatory/neurohormonal biomarkers enables more accurate risk stratification and supports personalized perioperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.